[Skip to Navigation]
Views 720
Citations 0
Invited Commentary
November 14, 2019

Economic Evaluation of Anti–Vascular Endothelial Growth Factor Therapy for Wet Age-Related Macular Degeneration

Author Affiliations
  • 1Center for Value-Based Medicine, Hilton Head, South Carolina
  • 2Wills Eye Hospital, Jefferson Medical University, Philadelphia, Pennsylvania
  • 3Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia
JAMA Ophthalmol. 2020;138(1):48-49. doi:10.1001/jamaophthalmol.2019.4582

In this issue of JAMA Ophthalmology, the article by Mulligan and colleagues1 provides evidence to support the conclusion that vascular endothelial growth factor (VEGF) inhibitor therapy for neovascular age-related macular degeneration (AMD) may yield a substantial financial return on investment to patients and society, depending on the number of quality-adjusted life-years (QALYs) gained from treatment. With an increased frequency of injections (more frequent injections) of 10.5 fixed injections per year for 5 years vs approximately 8 injections per year (less frequent injections) for 5 years with a treat-and-extend regimen, the 5-year patient financial benefits compared with no treatment increased from $9.9 billion to $17.0 billion.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words